Evidence map›Paper›PMID 37124293›Full record

ArticleJACS Au2023

Unexplored Facet of Pincer Ligands: Super-Reductant Behavior Applied to Transition-Metal-Free Catalysis.

Vikramjeet Singh, Rahul Singh, Arijit Singha Hazari, Debashis Adhikari

Open access · goldAbstract read
In one paragraph

Article in JACS Au, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Vikramjeet SinghDepartment of Chemical Sciences, Indian Institute of Science Education and Research Mohali, SAS Nagar 140306, India.
Rahul SinghDepartment of Chemical Sciences, Indian Institute of Science Education and Research Mohali, SAS Nagar 140306, India.
Arijit Singha HazariDepartment of Chemistry, Stuttgart University, Stuttgart 70174, Germany.
Debashis AdhikariDepartment of Chemical Sciences, Indian Institute of Science Education and Research Mohali, SAS Nagar 140306, India.ORCID https://orcid.org/0000-0001-8399-2962
Indian Institute of Science Education and Research Mohali · INUniversity of Stuttgart · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pincer ligands are well-established supporting ancillaries to afford robust coordination to metals across the periodic table. Despite their widespread use in developing homogeneous catalysts, the redox noninnocence of the ligand backbone is less utilized in steering catalytic transformations. This report showcases a trianionic, symmetric NNN-pincer to drive C-C cross-coupling reactions and heterocycle formation via C-H functionalization, without any coordination to transition metals. The starting substrates are aryl chlorides that can tease the limit of a catalyst's ability to promote a reductive cleavage at a much demanding potential of -2.90 V vs SCE. The reducing power of the simple trianionic ligand backbone has been tremendously amplified by shining visible light on it. The catalyst's success relies on its easy access to the one-electron oxidized iminosemiquinonate form that has been thoroughly characterized by X-band electron paramagnetic resonance spectroscopy through spectroelectrochemical experiments. The moderately long-lived excited-state lifetime (10.2 ns) and such a super-reductive ability dependent on the one-electron redox shuttle between the bisamido and iminosemiquinonato forms make this catalysis effective.

Identifiers

PMID37124293
PMCPMC10131200
OpenAlexW4363650190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.